CAIRNS HOSPITAL

ALYSSA TIEPPO & ZOE KLIBBE

Hamman Rich Syndrome

Case Study

58 yo male from Daintree

Previously well, presented with progressive SOB over 1 week

Associated with fever, chills, malaise, lethargy

Not on regular medication; smoked tobacco and marijuana

Worked as a firefighter previously

o/e: SpO2 90% RA, RR 26, BP 140/85, temp 36.4

Chest: fine crepitation over right lower zone

Laboratory

FBC: Hb 115, neutrophil 14.9, Plt 254

Na 126 (normal 135-145mmol/L, K 3.5 (normal: 3.5-5mmol/L), Cr 66 (normal: 65.4-119.3um/L)

LFT & coag profile within normal limits

VBG: pH 7.43, pCO2 28, pO2 54, HCO3 18

Sputum culture NAD

Impression

Diffused alveolitis with broad differentials

Treated with IV ceftriaxone, azithromycin

Supplemental O2

Microbiological screening

Autoimmune screening

Bronchoscopy & washing


Clinically improving

FEELING MUCH IMPROVED "BEST I'VE FELT IN YEARS"

HAPPY TO TRIAL OFF O2 CLINICALLY IMPROVING ILD

ABS CEASED

Rapidly Progressive Fibrosis



Initial CT 07/02/2017



14/02/17



| Spiromo | tn. | Ref | Pre | Pre |
|-----------|---------|------|------|-------|
| Spirome | uy | | Meas | % Ref |
| FEV1 | Liters | 3.44 | 3.36 | 98 |
| FVC | Liters | 4.34 | 4.39 | 101 |
| FEV1/FVC | % | 77 | 76 | |
| FEF25-759 | % L/sec | 3.65 | 2.76 | 76 |
| FEF50% | L/sec | 4.57 | 3.66 | 80 |
| PEF | L/sec | 8.54 | 9.78 | 115 |
| | | | | |





Lung Volumes

| TLC | Liters | 7.06 | 5.72 | 81 |
|-----------|--------|------|------|----|
| VC | Liters | 4.52 | 4.39 | 97 |
| RV | Liters | 2.36 | 1.32 | 56 |
| RV/TLC | % | 36 | 23 | |
| FRC PL | Liters | 3.58 | 3.39 | 94 |
| Diffusion | 2 | | | |

DLCO mL/mmHg/min 29.3 10.2 mL/mmHg/min DL Adj 29.3 11.9 VA Liters 5.19 (37) mL/mHg/min/L **DLCO/VA** 1.97 5.36 2.28 mL/mHg/min/L DLVA Adj

Initial DLFTs 15/02/2017

| 0 | Spirome | try | Ref | Pre | Pre |
|----------|-----------|--------------|------|-------|-------|
| | FEV1 | Liters | 244 | Meas | % Ref |
| | FVC | | 3.44 | 3.54 | 103 |
| | | Liters | 4.34 | 4.57 | 105 |
| | FEV1/FVÇ | | 77 | 77 | |
| | FEF25-759 | 6 L/sec | 3.65 | 3.01 | 82 |
| | FEF50% | L/sec | 4.57 | 4.26 | 93 |
| | PEF | L/sec | 8.54 | 11.48 | 134 |
| 0 | | | 0.01 | 11.40 | 134 |
| ml, | Lung Vol | lumes | | | |
| | TLC | Liters | 7.06 | 6.21 | 88 |
| | VC | Liters | 4.52 | 4.74 | |
| | RV | Liters | 2.36 | | 105 |
| | RV/TLC | % | | 1.47 | 62 |
| | FRC PL | | 36 | 24 | |
| STORES . | | Liters | 3.58 | 3.97 | 111 |
| CO | Diffusion | | | | |
| | DLCO | mL/mmHg/min | 29.3 | 13.1 | 45 |
| | DL Adj | mL/mmHg/min | 29.3 | 14.9 | 51 |
| | VA | Liters | | 5.39 | 01 |
| | DLCONA | mL/mHg/min/L | 5.36 | | 45 |
| | DL/VA Adj | mL/mHg/min/L | 3.30 | 2.42 | 45 |
| | ou Thai | monng/min/L | | 2.76 | |

Sequential DLFTs 20/02/2017

Discharged 24/02/17


Clinically improving despite hypermania secondary to steroids

Drop to 50mg prednisolone

Plan for DLFTs every 2 weeks after discharge

Repeat CXR before discharge and every 2 weeks after

DLCO & KCO Over Time



Final DLFTs - 09/12/2021

| 1 | 0-1 | | Ref | Pre | Pre | |
|---------|-----------|--------------|------|------|-------|--|
| | Spiromet | ry | | Meas | % Ref | |
| | FEV1 | Liters | 3.44 | 3.36 | 98 | |
| | FVC | Liters | 4.34 | 4.39 | 101 | |
| | FEV1/FVC | % | 77 | 76 | | |
| | FEF25-75% | L/sec | 3.65 | 2.76 | 76 | |
| | FEF50% | L/sec | 4.57 | 3.66 | 80 | |
| | PEF | L/sec | 8.54 | 9.78 | 115 | |
| 0 | | | | | | |
| now, | Lung Vol | umes | | | | |
| | TLC | Liters | 7.06 | 5.72 | 81 | |
| | VC | Liters | 4.52 | 4.39 | 97 | |
| | RV | Liters | 2.36 | 1.32 | 56 | |
| - | RV/TLC | % | 36 | 23 | | |
| 4 | FRC PL | Liters | 3.58 | 3.39 | 94 | |
| and and | Diffusion | | | | | |
| | DLCO | mL/mmHg/min | 29.3 | 10.2 | 35 | |
| | DL Adj | mL/mmHg/min | 29.3 | 11.9 | 40 | |
| | VA | Liters | 20.0 | 5.19 | -10 | |
| | DLCO/VA | mL/mHg/min/L | 5.36 | 1.97 | 37 | |
| | DLVA Adj | mL/mHg/min/L | | 2.28 | | |
| | , | 9 | | 0 | | |

Spirometry

| | | Pred | LLN | Pre | %Ref | 5 4 3 2 1 Pred 1 2 3 | Post |
|------------|-----|-------|-------|-------|-------|----------------------|------|
| FEV1 | L | 3.51 | 2.60 | 2.83 | 80.7 | 0 | |
| FVC | L | 4.57 | 3.46 | 4.81 | 105.1 | | |
| FEV1 % FVC | % | 75.87 | 64.08 | 58.78 | 77.5 | 0 | |
| PEF | L/s | 8.43 | 6.44 | 7.83 | 92.9 | 0 | |

Lung Volumes

| | | Pred | LLN | Pre | %Ref | -5 -4 -3 -2 -1 Pred 1 2 3 | Post |
|--------|---|-------|-------|-------|-------|---------------------------|------|
| TLC | L | 7.31 | 5.84 | 7.97 | 109.1 | | |
| VC MAX | L | 5.00 | 3.99 | 4.87 | 97.4 | | |
| FRCpl | L | 3.79 | 2.62 | 4.93 | 129.9 | 0 | |
| RV | L | 2.37 | 1.45 | 3.09 | 130.5 | 0 | |
| RV%TLC | % | 31.85 | 21.82 | 38.75 | 121.6 | 0 | |

Gas Transfer

| | | Pred | LLN | Pre | %Ref | 5 4 3 2 1 Pred 1 2 3 |
|---------|-----------------|-------|-------|-------|-------|----------------------|
| DLCO_SB | ml/(min*mmHg) | 27.33 | 20.36 | 16.61 | 60.8 | 3 |
| DLCOcSB | ml/(min*mmHg) | 27.33 | 20.36 | 17.70 | 64.8 | 0 |
| VA_SB | L | 6.61 | 5.34 | 6.85 | 103.6 | |
| KCO_SB | ml/(min*mmHg*L) | 4.16 | 3.13 | 2.43 | 58.3 | 3 |
| KCOc_SB | ml/(min*mmHg*L) | 4.16 | 3.13 | 2.58 | 62.1 | 3 |
| VIN_SB | L | 5.00 | 3.99 | 4.81 | 96.2 | |
| Hb | g(Hb)/dL | | | 12.60 | | |

15/02/2017

09/12/2021

Summary

Clinically and radiologically improved during admission

Discharged after 18 days admission on oral prednisone

Discharged from OPD December 2021 after remaining stable

Hamman Rich history



Described by Louis Hamman and Arnold Rich in 1935

Known as acute interstitial pneumonitis

Acute onset and rapid progressive course

Epidemiology

Prevalence 1-9/100 000 Affects previously healthy individuals

Mean age 50-55 years

No gender predominance

Not associated with cigarette smoking

Clinical Presentation

Rapid onset with myalgia, arthralgia, chills, malaise

Fever, cough, progressive breathlessness


Tachypnoea and diffused crackles on chest exam


Hypoxemic respiratory failure requiring ventilatory support within a few days

Broad Differentials for Diffuse Alveolitis

| Ethch | lorvynol |
|-----------|-----------------------------|
| Aspiri | /2/2014 (B) (C) (C) |
| Radia | tion therapy |
| Oxyg | en toxicity |
| Heroi | n |
| Cocai | ne |
| Toxic inh | nalants |
| Chlor | ine gas |
| Nitrog | gen dioxide |
| Phoso | gene |
| Smok | ie e |
| Ingesta | nts |
| Parag | uat |
| Keros | ene |
| Rapes | seed oil-toxic oil syndrome |
| Connect | tive tissue disease |

Lung Biopsy – Histology





Normal lung

Prognosis

In-hospital mortality > 50%

Most initial survivors die within 6 months of presentation

Recurrence has been reported

Management

Consider Hamman Rich early and treat aggressively

Respiratory support

Glucocorticosteroids

Consider empirical antibiotics

Consider Lung transplantation



Questions?